arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

LIGAND PHARMACEUTICALS INC

LGND
$299.14 ▼ -17.03 (-5.39%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
69 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
77
Health
Good
Bullish
auto_awesome

Analytical Summary

LIGAND PHARMACEUTICALS INC shows strong fundamentals with top-quartile Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $6.0B
Dividend Yield —
Revenue Growth -31.8% ↘
Op. Margin -20.0% ↘
ROIC -0.5% ↘
FCF / Share $-1.39 ↘
Trailing P/E —
Price / Book 6.2x
FCF Yield —
Debt / Equity 1.17
info Valuation on last close. End-of-day price, Nov 5, 2026.

69-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$78.75M
↓ -31.8% —
Net Income Profit after all expenses
$-13.35M
— 0.0% —
Operating Margin Operating profit as % of sales
-20.0%
↓ -248.4% 67th
FCF / Share Free cash flow per share
$-1.39
↓ -216.2% —
Long-Term Debt Long-term obligations
$1.13B
— +0.1% —
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↓
82
Returns ↑
74
Financial Health ↑
96
Cash Quality ↓
36

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 19 years · 69 quarters